Assessment of the appropriate use criteria for amyloid PET in an unselected memory clinic cohort: The ABIDE project.


Journal

Alzheimer's & dementia : the journal of the Alzheimer's Association
ISSN: 1552-5279
Titre abrégé: Alzheimers Dement
Pays: United States
ID NLM: 101231978

Informations de publication

Date de publication:
11 2019
Historique:
received: 12 03 2019
revised: 01 06 2019
accepted: 01 07 2019
pubmed: 9 10 2019
medline: 1 9 2020
entrez: 10 10 2019
Statut: ppublish

Résumé

The objective of this study was to assess the usefulness of the appropriate use criteria (AUC) for amyloid imaging in an unselected cohort. We calculated sensitivity and specificity of appropriate use (increased confidence and management change), as defined by Amyloid Imaging Taskforce in the AUC, and other clinical utility outcomes. Furthermore, we compared differences in post-positron emission tomography diagnosis and management change between "AUC-consistent" and "AUC-inconsistent" patients. Almost half (250/507) of patients were AUC-consistent. In both AUC-consistent and AUC-inconsistent patients, post-positron emission tomography diagnosis (28%-21%) and management (32%-17%) change was substantial. The Amyloid Imaging Taskforce's definition of appropriate use occurred in 55/507 (13%) patients, detected by the AUC with a sensitivity of 93%, and a specificity of 56%. Diagnostic changes occurred independently of AUC status (sensitivity: 57%, specificity: 53%). The current AUC are not sufficiently able to discriminate between patients who will benefit from amyloid positron emission tomography and those who will not.

Identifiants

pubmed: 31594684
pii: S1552-5260(19)35124-6
doi: 10.1016/j.jalz.2019.07.003
pii:
doi:

Substances chimiques

Amyloid 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1458-1467

Informations de copyright

Copyright © 2019 The Authors. Published by Elsevier Inc. All rights reserved.

Auteurs

Arno de Wilde (A)

Department of Neurology, Amsterdam Neuroscience, Alzheimer Center, VU University, Amsterdam UMC, Amsterdam, the Netherlands. Electronic address: a.dewilde@amsterdamumc.nl.

Rik Ossenkoppele (R)

Department of Neurology, Amsterdam Neuroscience, Alzheimer Center, VU University, Amsterdam UMC, Amsterdam, the Netherlands; Department of Radiology and Nuclear Medicine, Amsterdam Neuroscience, VU University, Amsterdam UMC, Amsterdam, the Netherlands; Clinical Memory Research Unit, Lund University, Malmö, Sweden.

Wiesje Pelkmans (W)

Department of Neurology, Amsterdam Neuroscience, Alzheimer Center, VU University, Amsterdam UMC, Amsterdam, the Netherlands.

Femke Bouwman (F)

Department of Neurology, Amsterdam Neuroscience, Alzheimer Center, VU University, Amsterdam UMC, Amsterdam, the Netherlands.

Colin Groot (C)

Department of Neurology, Amsterdam Neuroscience, Alzheimer Center, VU University, Amsterdam UMC, Amsterdam, the Netherlands; Department of Radiology and Nuclear Medicine, Amsterdam Neuroscience, VU University, Amsterdam UMC, Amsterdam, the Netherlands.

Ingrid van Maurik (I)

Department of Neurology, Amsterdam Neuroscience, Alzheimer Center, VU University, Amsterdam UMC, Amsterdam, the Netherlands.

Marissa Zwan (M)

Department of Neurology, Amsterdam Neuroscience, Alzheimer Center, VU University, Amsterdam UMC, Amsterdam, the Netherlands.

Maqsood Yaqub (M)

Department of Radiology and Nuclear Medicine, Amsterdam Neuroscience, VU University, Amsterdam UMC, Amsterdam, the Netherlands.

Frederik Barkhof (F)

Department of Radiology and Nuclear Medicine, Amsterdam Neuroscience, VU University, Amsterdam UMC, Amsterdam, the Netherlands; Institutes of Neurology and Healthcare Engineering, UCL, London, UK.

Adriaan A Lammertsma (AA)

Department of Radiology and Nuclear Medicine, Amsterdam Neuroscience, VU University, Amsterdam UMC, Amsterdam, the Netherlands.

Geert Jan Biessels (GJ)

Department of Neurology and Neurosurgery, Brain Center Rudolf Magnus, University Medical Center Utrecht, Utrecht, the Netherlands.

Philip Scheltens (P)

Department of Neurology, Amsterdam Neuroscience, Alzheimer Center, VU University, Amsterdam UMC, Amsterdam, the Netherlands.

Bart N van Berckel (BN)

Department of Neurology, Amsterdam Neuroscience, Alzheimer Center, VU University, Amsterdam UMC, Amsterdam, the Netherlands; Department of Radiology and Nuclear Medicine, Amsterdam Neuroscience, VU University, Amsterdam UMC, Amsterdam, the Netherlands.

Wiesje M van der Flier (WM)

Department of Neurology, Amsterdam Neuroscience, Alzheimer Center, VU University, Amsterdam UMC, Amsterdam, the Netherlands; Department of Epidemiology and Biostatistics, Amsterdam Neuroscience, VU University of Amsterdam, Amsterdam, the Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH